Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Trial record 1 of 3 for:    Lutonix BTK
Previous Study | Return to List | Next Study

Lutonix DCB Versus Standard Balloon Angioplasty for Treatment of Below-The-Knee (BTK) Arteries

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2017 by C. R. Bard
Sponsor:
Collaborator:
Bard Ltd
Information provided by (Responsible Party):
C. R. Bard
ClinicalTrials.gov Identifier:
NCT01870401
First received: May 7, 2013
Last updated: March 23, 2017
Last verified: March 2017
  Purpose
To assess the safety and efficacy of the Lutonix Drug Coated Balloon (DCB) for treatment of stenosis or occlusion of native below-the-knee arteries.

Condition Intervention
Critical Limb Ischemia
Device: Lutonix DCB
Device: Uncoated PTA Catheter

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant
Primary Purpose: Treatment
Official Title: A Prospective, Multicenter, Single Blind, Randomized, Controlled Trial Comparing the Lutonix Drug Coated Balloon Versus Standard Balloon Angioplasty for Treatment of Below-the-Knee (BTK) Arteries(Lutonix BTK Trial)

Resource links provided by NLM:


Further study details as provided by C. R. Bard:

Primary Outcome Measures:
  • Freedom from BTK MALE+POD [ Time Frame: 30 days ]
    Composite of all-cause death, above-ankle amputation or major reintervention

  • Limb Salvage [ Time Frame: 6 months ]
    Freedom from the composite of above ankle amputation

  • Primary Patency [ Time Frame: 6 months ]
    Freedom from target vessel occlusion and clinically driven target lesion reintervention


Secondary Outcome Measures:
  • Wound healing [ Time Frame: 30 days; 6 months, 12 months, 24 months, and 36 months ]
    Healed or not, if not, improving, stagnant, worsening

  • Primary Patency [ Time Frame: 30 days and at 6 months, 12 months, 24 months, and 36 months ]
    Freedom from occlusion without clinically-driven Target Lesion Revascularization (TLR)

  • Hemodynamic outcome [ Time Frame: 30 days and at 6 months, 12 months, 24 months, and 36 months ]
    change in toe & ankle pressures

  • Clinically-driven TLR [ Time Frame: 30 days and at 6, 12, 24, and 36 months ]
    Revascularization performed on all randomized patients who returned with clinical symptoms, and if the subject has a target lesion diameter stenosis ≥ 50%.

  • Limb salvage in surviving subjects [ Time Frame: 30 days and at 6, 12, 24, and 36 months ]
    No Amputation of target limb


Estimated Enrollment: 1000
Study Start Date: May 2013
Estimated Study Completion Date: June 2020
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Lutonix DCB
Lutonix Paclitaxel Drug Coated Balloon
Device: Lutonix DCB
Other Name: LTX DCB
Active Comparator: PTA Catheter
Standard Uncoated PTA Catheter
Device: Uncoated PTA Catheter
Other Name: PTA

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or non-pregnant female ≥18 years of age;
  • Rutherford Clinical Category 3, 4 & 5;
  • Life expectancy ≥ 1 year;
  • Significant stenosis (≥70%)
  • A patent inflow artery;
  • Target vessel(s) diameter between 2 and 4 mm;
  • Target vessel(s) reconstitute(s) at or above the ankle

Exclusion Criteria:

  • Pregnant or planning on becoming pregnant;
  • History of stroke within 3 months;
  • History of MI, thrombolysis or angina within 30 days of enrollment;
  • Planned major amputation (of either leg)
  • Prior major amputation if amputation occurred less than one year prior to enrollment and if patient is not independently ambulating;
  • GFR ≤ 30 ml/min per 1.73m2;
  • Acute limb ischemia;
  • In-stent restenosis of target lesion
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01870401

Contacts
Contact: Kelly Erickson kelly.erickson@crbard.com

  Show 61 Study Locations
Sponsors and Collaborators
C. R. Bard
Bard Ltd
Investigators
Principal Investigator: Patrick Geraghty, MD Washington University School of Medicine
Principal Investigator: Jihad Mustapha, MD Metro Health Hospital
Principal Investigator: Marianne Brodmann, MD Medical University Graz, Austria
  More Information

Responsible Party: C. R. Bard
ClinicalTrials.gov Identifier: NCT01870401     History of Changes
Other Study ID Numbers: CL0005-01
Study First Received: May 7, 2013
Last Updated: March 23, 2017

Additional relevant MeSH terms:
Ischemia
Pathologic Processes

ClinicalTrials.gov processed this record on May 22, 2017